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Heterozygous mutations in MSX2 are responsible for an autosomal dominant form of parietal foramina (PFM).
PFM are oval defects of the parietal bones that are also a characteristic feature of a contiguous gene–deletion
syndrome caused by a proximal deletion in the short arm of chromosome 11 (Potocki-Shaffer syndrome). We have
identified a human bacterial artificial chromosome (BAC) clone mapping to chromosome 11, containing a region
homologous to the human homeobox gene MSX2. Further sequence analysis demonstrated that the human ortho-
logue (ALX4) of the mouse Aristaless-like 4 gene (Alx4) is contained within this 11p clone. We used FISH to test
for the presence—or for the heterozygous deletion—of this clone in two patients with the 11p11.2-deletion syndrome
and showed that this clone is deleted in these patients. ALX4 and Alx4 were shown to be expressed in bone and
to be absent from all other tissues tested. The involvement of Alx4 in murine skull development, its bone-specific
expression pattern, the fact that Alx4 is a dosage-sensitive gene in mice, and the localization of a human genomic
clone containing ALX4 to 11p11.2, with hemizygosity in patients with deletion of 11p11.2 who have biparietal
foramina, support the contention that ALX4 is a candidate gene for the PFM in the 11p11.2-deletion syndrome.
Parietal foramina are the result of delayed or incomplete
ossification of the parietal bones of the skull. Parietal
foramina can occur as either an isolated autosomal dom-
inant trait (PFM [MIM 168500]) or as part of a syn-
drome. One such syndrome is the contiguous gene–
deletion syndrome (CGDS) caused by monosomy of
11p11.2 (Potocki-Shaffer syndrome) (Shaffer et al. 1993;
Bartsch et al. 1996; Potocki and Shaffer 1996; Wuyts et
al. 1999). The Potocki-Shaffer syndrome (PSS [MIM
601224]), includes biparietal foramina, multiple exos-
toses (MIM 133701), dysmorphic features, and mental
retardation (Shaffer et al. 1993; Bartsch et al. 1996;
Potocki and Shaffer 1996; Wuyts et al. 1999).
Recently, autosomal dominant, isolated parietal fo-
ramina were found to be the result of mutations in
the homeobox gene MSX2, which maps to 5q34-q35
(Wilkie et al. 2000; Wuyts et al. 2000). Mutations re-
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sulting in PFM were either entire-gene deletions or loss-
of-function mutations, which supports the hypothesis
that haploinsufficiency of this protein results in PFM.
This possibility is distinct from the previously described
gain-of-function mutation inMSX2, which is associated
with craniosynostosis (Jabs et al. 1993; Ma et al. 1996).
Mice with loss-of-function homozygous mutations in
Msx2 display a number of anomalies, including defects
in skull ossification (Satokata et al. 2000).
CGDS refers to conditions caused by haploinsuffi-
ciency of multiple, functionally unrelated yet physically
contiguous loci (Schmickel 1986; Schinzel 1988). The
challenge in studying any CGDS is in proving that hap-
loinsufficiency of one particular gene within the deletion
interval causes a specific clinical feature of the syndrome.
Few examples exist whereby a gene has been shown,
through identification of mutations in individuals or
families showing the isolated clinical anomaly, to be the
causative gene of a single feature (reviewed in Shaffer et
al. 2001).
Given that haploinsufficiency of MSX2 results in
PFM, we hypothesized that an MSX2 homologue could
be responsible for the PFM in the 11p11.2-deletion syn-
drome. Our approach was to use the MSX2 sequence
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Figure 1 Representative FISH results. BAC 706A13 is labeled with digoxigenin and is detected with anti-digoxigenin conjugated to
rhodamine (fluoresces red). The centromere of chromosome 11 is identified by an alpha-satellite probe labeled with biotin and is detected by
avidin conjugated to fluorescein (fluoresces green). A, Control metaphase showing localization of clone 706A13 to the proximal short arm of
chromosome 11. B and C, Cell lines derived from patients with 11p11.2 deletions and with PSS. B, Patient originally reported by Shaffer et
al. (1993). C, Patient originally reported by Potocki and Shaffer (1996). Arrows indicate the deleted chromosome for each patient.
to identify the 11p-specific gene responsible for PFM in
PSS.
The complete coding sequence of human MSX2 was
used to perform a BLASTN homology search against the
high-throughput genome-sequence database (BLAST).
The human clone RP11-706A13 (GenBank accession
number AC019143), previously mapped to chromosome
11, was identified and obtained from the BAC-PAC Re-
sources at Children’s Hospital Oakland Research Insti-
tute (CHORI). The region of homology in clone 706A13
corresponds to 26 bp of 100% identity to MSX2, in
only the homeodomain region (E value p 9 # 104).
Two-colored FISH, using 706A13 labeled with digox-
igenin 11-dUTP and a chromosome 11 centromeric
probe (ONCOR) labeled with biotin 16-dUTP, was per-
formed simultaneously on denatured metaphase spreads
of chromosomally normal control individuals. The FISH
analysis showed that clone 706A13 localized to the
proximal short arm of chromosome 11 (fig. 1A). Two
patients with dysmorphic features, biparietal foramina,
multiple exostoses, and mental retardation were ascer-
tained by clinical geneticists at Baylor College of Med-
icine, as has been reported elsewhere (Shaffer et al. 1993;
Bartsch et al. 1996; Potocki and Shaffer 1996). FISH
analysis of these two cell lines showed that 706A13 was
deleted in both cases (fig. 1B and C).
A homology search using sequence flanking the ho-
meobox domain on clone 706A13 was performed and
resulted in the identification of significant homology to
the mouse Alx4 coding sequence. Alx4 is a homeobox
gene, which has been shown to be involved in skull and
limb development in mice (Qu et al. 1997b, 1998). A
BLASTN search using the full mouse Alx4 cDNA iden-
tified four, unordered, nonoverlapping fragments con-
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Table 1







ATG AAT GCT…CCT GCT ACG gtgagtgcacg
tcctccctcag CTA AAG AGA…CGC GTG CAG gtcagtgaggg
gcgtcttgtag GTC TGG TTC…TAC GCC CAG gtaagtcccgc
tcctctcccag ATT CAG AAC…GCC ACA TGA
Figure 2 Diagrammatic representation of regions of homology between human ALX4 sequence (top, green) and mouse Alx4 (bottom,
yellow). BAC 706A13 is indicated in gray (middle). Pink areas denote coding regions, and the percentages of identity between ALX4 and Alx4
are given in each area. Blue regions denote intronic sequence. Letters “a”–“d” indicate four different BAC 706A13 fragments used to assemble
the human cDNA. Black arrows indicate position and direction of primers designed to obtain the human sequence, not present in the mouse
cDNA (see text).
tained within BAC 706A13 (fig. 2). Sequence compar-
ison of Alx4 and these BAC fragments showed extensive
and significant homology, with the exception of certain
specific regions as shown in figure 2. This finding in-
dicates that the human orthologue of Alx4 (ALX4) is
contained within clone 706A13.
ALX4 primers were designed from BAC 706A13 se-
quence between base pair 151246 and base pair 151803,
with the PCR product corresponding to the coding re-
gion from amino acid 1 to amino acid 156, and from
sequence between base pair 25355 to base pair 25582,
corresponding to the coding region from amino acid 382
to the last codon. These regions represent sequence pres-
ent in the BAC but not corresponding to the mouse
cDNA (fig. 2). Nested reverse transcriptase–PCR (RT-
PCR) (SUPERSCRIPT First-Strand Synthesis System;
Gibco) was performed to obtain the sequence residing
between these primer pairs. b-actin was used as a pos-
itive control. The PCR products were sequenced and
confirmed that ALX4 is contained within clone 706A13,
which allowed for the full length of humanALX4 cDNA
to be assembled and compared with theAlx4 cDNA (fig.
2). The full-length ALX4 cDNA is 1,583 bp and codes
for a 410-amino-acid protein (start codon at base pair
105 and stop codon at base pair 1337). The exon/intron
boundaries of ALX4 were obtained by sequence com-
parison between the cDNA and the genomic BAC clones
(table 1). The gene contains at least four exons (fig. 2).
The nucleotide-sequence comparison showed 88% iden-
tity between the orthologues. Predicted amino acid com-
position (BLASTX) showed 80% identity and 83% sim-
ilarity between the two predicted proteins (fig. 3).
The tissue-specific expression patterns were investi-
gated, for both Alx4 and ALX4. For all experiments, b-
actin was used as a positive control. On the basis of
northern blot analysis (Clontech), we confirmed that
Alx4 is not expressed in mouse heart, brain, spleen, lung,
liver, skeletal muscle, kidney, or testis (data not shown)
(Qu et al. 1997a); however, Alx4 expression was evident
in cultured mouse osteoblasts as assayed by RT-PCR.
This expression pattern is consistent with that reported
for the whole mount in situ of mouse embryos, in which
expression is seen in both the craniofacial region and
the anterior aspect of the developing limb buds (Qu et
al. 1997b). Expression studies of human ALX4 dem-
onstrated no detectable transcript on a northern blot
assay of human heart, brain, placenta, lung, liver, skel-
etal muscle, kidney, pancreas, spleen, thymus, prostate,
testis, uterus, small intestine, colon, or peripheral blood
leukocytes (Clontech) (data not shown). However,
nested RT-PCR with primers to ALX4 on parietal bone,
obtained from a newborn who died of arrhythmia, dem-
onstrated expression (fig. 4). Thus, ALX4 expression is
likely to be restricted to bone, and we have demonstrated
such expression specifically in parietal bone, the region
of defect in PFM.
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Figure 3 Comparison of predicted protein sequence of human
ALX4 (hALX4) to mouse Alx4 (mAlx4). Identical amino acids are
denoted by two vertical dots, similar amino acids are denoted by a
single dot, and blank spaces denote nonidentity. Dashed lines denote
regions of ALX4 not represented in Alx4. The boxed area indicates
the location of the homeobox domain.
Figure 4 Results of nested RT-PCR with primers to ALX4,
showing strong expression in parietal bone (lanes 1 and 2) and weak
expression in a lymphoblast cell line of a normal individual (lane 3).
Outside primers are as follows: ALX4OF, 5′-CTCCTCGCCTCCCCA-
AACTC-3′; and ALX4OR, 5′-CCTCCCTCCCAGCAGTCCAC-3′. In-
side primers are as follows: ALX4IF, 5′-GGGGCCAGCAGCGTCA-
CC-3′; and ALX4IR, 5′-CTTGGGGCGGCTGAAAGTG-3′.
Herein, we report the identification of a human ge-
nomic clone containing a homeobox gene orthologous
to mouse Alx4. This clone maps to proximal 11p (band
p11.2), the region deleted in PSS. This clone was iden-
tified on the basis of a very short region of homology
to MSX2 and was shown to contain the sequence en-
coding the human ALX4 gene. ALX4 encodes a pu-
tative transcription factor that is among the paired-
class homeoproteins (Qu et al. 1997a). This gene is
similar to the Drosophila gene aristaless, which binds
palindromic DNA sequences (5′-TAAT-3′) as either ho-
modimers or as heterodimers with other family mem-
bers (Tucker and Wisdom 1999). The murine ortho-
logue, Alx4, is expressed at several sites during devel-
opment, including the craniofacial and limb-bud
mesenchyme (Qu et al. 1997b). Homozygous null mu-
tants of Alx4 show ventral body-wall defects, preax-
ial polydactyly, and decreased size of the parietal plate
of the skull (Qu et al. 1997b). In these Alx4-mutant
mice, ossification of the parietal bone did not extend
over the superior aspect of the skull (Qu et al. 1997b).
This is in contrast to what was seen in wild-type mice
and may be due to a delay in bone development (Qu
et al. 1997b). For the most part, the skeletal anomalies
seen in the Alx4-mutant mice are abnormalities of ei-
ther membranous ossification or endochondral ossifi-
cation (Qu et al. 1997b). As is often seen when a cor-
relation between a mouse mutation and the human
condition is made, the analysis of Alx4-targeted mu-
tations failed to reveal any phenotypic alteration in
heterozygous mice. However, the penetrance of the
polydactyly phenotype in heterozygotes appears to be
dependent on the specific mouse strain (Qu et al. 1998).
This same phenomenon may apply to the other aspects
of the homozygous phenotype, including the craniofa-
cial anomalies (Qu et al. 1998). The Strong’s luxoid
mutant, 1st, recently has been shown to be the result
of loss-of function mutations in Alx4 (Qu et al. 1998).
In addition to craniofacial defects, polydactyly, and
other anomalies, the male mice have anomalies of the
phallus (Forsthoefel 1963; Qu et al. 1998). This in-
cludes both reduction of the pubic bone and a short-
ened phallus that is not well separated from the scrotal
swellings (Forsthoefel 1963). Forsthoefel (1963) spec-
ulated that this is the result of retarded growth of the
underlying mesenchyme of the pubic bone and phallus.
This might be the correlate of the micropenis seen in
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males with PSS (Shaffer et al. 1993). Moreover, Alx4
maps to mouse chromosome 2, a region of conserved
synteny with human 11p12q12 (Mouse Genome In-
formatics). This predicts that human ALX4—and any
syndromes that may result from mutation at this lo-
cus—would likely map to the pericentromeric region
of chromosome 11 (Qu et al. 1998; also see Mouse
Genome Informatics). Given that the mouse Alx4 is
involved in craniofacial development and that mice that
are mutant for this gene show a decrease in the size of
the parietal bone (Qu et al. 1997b), ALX4 is a good
candidate for PFM in cases of del(11)(p11.2p12).
Elsewhere, we have described a CGDS due to a mi-
crodeletion of the proximal short arm of chromosome
11 (Shaffer et al. 1993; Potocki and Shaffer 1996). Some
of the features of this CGDS can be found as isolated
Mendelian traits—specifically, the multiple exostoses
that are caused by haploinsufficiency for the EXT2 gene
(Stickens et al. 1996; Wuyts et al. 1996; Ligon et al.
1998). PFM is another clinical finding of this CGDS.
There are several lines of evidence indicating that human
ALX4 is responsible for the PFM seen in patients with
the 11p11.2-deletion syndrome. First, the murine ortho-
logue, Alx4, is expressed in craniofacial mesenchyme
during embryogenesis and is involved in skull develop-
ment. Second, mutations in this gene in mice cause a
decrease in the size of the parietal bone, among other
craniofacial and developmental features. Third, as dem-
onstrated by the present report, a gene showing signif-
icant homology with mouse Alx4maps to proximal 11p
and is deleted in two patients with craniofacial anom-
alies, including parietal foramina. Fourth, ALX4 and
Alx4 appear to be expressed exclusively in bone, and
ALX4 has been demonstrated to be expressed in parietal
bone. Finally, ALX4 has been identified through ho-
mology searches using MXS2, a gene that encodes a
homeobox protein and that, by mutation analysis, has
been shown to cause parietal foramina in some families.
Further functional studies and identification of iso-
lated mutations in patients with autosomal dominant
forms of PFM will be required in order to allow char-
acterization of the role of ALX4 in the PFM defect seen
in 11p-deletion patients. Patients with the PSS deletion
show multiple exostoses caused by haploinsufficiency of
EXT2, PFM, and mental retardation. It is likely that
ALX4 is indeed the cause of PFM in this syndrome.
Complete characterization of the molecular basis of PSS
awaits the identification of a mental retardation locus
within 11p11.2.
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